Marina Biotech, Inc. (NASDAQ: MRNA) reached up 47.81% in morning trading to $.2025 with 6M shares traded. Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm SA for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Marina Biotech, Inc. (NASDAQ: MRNA - News) today announced that the Marina/Debiopharm Research and Development (R&D) Team has selected and confirmed the lead DiLA2 formulation for a RNAi-based therapy for the treatment of non-muscle invasive bladder cancer.
Qiao Xing Universal Resources, Inc. (NASDAQ: XING) reached up 17.14% in morning trading to $.8903 with 550K shares traded. Qiao Xing Universal Resources, Inc. is a leading player in the molybdenum mining industry with substantial assets in the resources industry. XING focuses on mining and processing rare metal ores and several strategically important base-metal ores, including molybdenum, copper lead and zinc. XING currently owns a 100% equity interest in Balinzuo Banner Xinyuan Mining Co., Ltd. and a 34.53% equity interest in Chifeng Aolunhua Mining Co., Ltd, as well as the right to receive 100% of the expected economic residual returns from Chifeng Haozhou Mining Co., Ltd. Qiao Xing Universal Resources, Inc. (NASDAQ: XING - News) today announced that it has signed a letter of intent ("LOI") to acquire a 100% equity interest in a company (the "Target Company") that owns an open-pit marble mine (the "Mine") located in Guzhang County, Hunan province, China , from an independent third party (the "Vendor").
Radient Pharmaceuticals Corporation (OTCQX:RXPC) (PINK:RXPC) reached up 30.23% in morning trading to $.0056 with 10M shares traded. Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. Radient Pharmaceuticals Corporation (OTCQX:RXPC.PK - News) (OTCPK:RXPC.PK - News) today announced it has completed restructurings with each of the company's 2011 Noteholders (who hold convertible notes and shares of Series A Convertible Preferred Stock) and Alpha Capital Anstalt ("Alpha") and Whalehaven Capital Fund Ltd. ("Whalehaven").
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
